Featured
Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing
Read ArticleDecoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
Read ArticleDecoy Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recently Announced Global Access Commitment Agreement
Read ArticleDecoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform
Read ArticleSalarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics
Read ArticleSalarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
Read ArticleSalarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform
Read ArticleYou have reached the end of the articles.
